Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01449058




Registration number
NCT01449058
Ethics application status
Date submitted
6/10/2011
Date registered
7/10/2011
Date last updated
2/10/2017

Titles & IDs
Public title
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Scientific title
A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Secondary ID [1] 0 0
2011-002578-21
Secondary ID [2] 0 0
CMEK162X2109
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced and Selected Solid Tumors 0 0
AML 0 0
High Risk and Very High Risk MDS 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BYL719
Treatment: Drugs - MEK162

Experimental: BYL719 + MEK162 - BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162


Treatment: Drugs: BYL719
taken orally

Treatment: Drugs: MEK162
taken orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Dose Limiting Toxicities (DLT)
Timepoint [1] 0 0
during the first cycle (28 days) of treatment with BYL719 and MEK162
Secondary outcome [1] 0 0
Number of participants with adverse events and serious adverse events
Timepoint [1] 0 0
Assessed from Cycle 1 Day 1 until treatment discontinuation
Secondary outcome [2] 0 0
Overall response rate
Timepoint [2] 0 0
Assessed every 8 weeks until disease progression
Secondary outcome [3] 0 0
Time to progression
Timepoint [3] 0 0
Assessed every 8 weeks until disease progression
Secondary outcome [4] 0 0
Progression free survival
Timepoint [4] 0 0
Assessed every 8 weeks until disease progression
Secondary outcome [5] 0 0
Time versus plasma concentration profiles of BYL719 and MEK162
Timepoint [5] 0 0
Assessed during the first cycle of treatment
Secondary outcome [6] 0 0
Correlation of baseline mutation or amplification status (PIK3CA, KRAS, NRAS and BRAF) and clinical anti-tumor activity outcome
Timepoint [6] 0 0
Assessed at Baseline (pre-treatment)
Secondary outcome [7] 0 0
Clinical benefit rate
Timepoint [7] 0 0
Assessed every 4 weeks for 3 months and every 3 months for 6 months followed by every 6 months thereafter until disease progression

Eligibility
Key inclusion criteria
* Histologically/cytologically confirmed, advanced solid tumors, AML or high risk and very high risk MDS
* Measurable disease as determined by RECIST 1.1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Primary CNS tumor or CNS tumor involvement
* Diabetes mellitus
* Unacceptable ocular/retinal conditions
* Clinically significant cardiac disease or impaired cardiac function

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/08/2017
Sample size
Target
Accrual to date
Final
139
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Array BioPharma Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
United States of America
State/province [7] 0 0
Utah
Country [8] 0 0
France
State/province [8] 0 0
Villejuif Cedex
Country [9] 0 0
Italy
State/province [9] 0 0
MI
Country [10] 0 0
Italy
State/province [10] 0 0
RM
Country [11] 0 0
Spain
State/province [11] 0 0
Catalunya
Country [12] 0 0
Switzerland
State/province [12] 0 0
Bellinzona
Country [13] 0 0
United Kingdom
State/province [13] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Array BioPharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Array BioPharma
Address 0 0
303-381-6604
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01449058